PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, April 04, 2022 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company”) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals is pleased to announce that Rachael Schumaker has accepted a position with the Company as its new Business Development Manager for the Midwest Region of the United States.
“The addition of Rachael to our sales and distribution team is a tremendous stride towards successfully accomplishing the short and long-term corporate and sales goals for PetVivo,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “We believe Rachael will be a key contributor to the introduction of our revolutionary product Spryng™ with OsteoCushion™ technology to veterinarians throughout the United States”
Ms. Schumaker has more than 20 years of experience related to management, marketing and distribution of veterinary products in the United States. She has served in various roles in product promotion, product distribution, technical sales, marketing, farm management software and supply chain management with companies such as Covetrus/Henry Schein Animal Health, Conservis Corporation, and Merial Limited, an entity that merged with Boehringer Ingelheim Animal Health. Ms. Schumaker is a graduate of Slippery Rock University of Pennsylvania with a degree in Communications.
“I am incredibly excited to have the opportunity to join the PetVivo sales and marketing team. It is a pleasure to be part of a team that possesses vast experience in the development and commercialization of life changing medical devices,” said Ms. Schumaker. “PetVivo’s veterinary medical device, Spryng with OsteoCushion technology, has been shown to improve the medical outcomes of animals suffering from lameness and other joint related afflictions, such as osteoarthritis, thereby enhancing the lives of companion animals and their owners.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of nineteen patents protects the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG, a veterinarian-administered, intraarticular injection for the treatment of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale to veterinarians.
John Lai, CEO
PetVivo Holdings, Inc.
Email: [email protected]
Forward-Looking commercial Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company’s common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.